newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEKTAR THERAPEUTICS

  • Explicit Guidance:

    • Clinical Trial Topline Readouts: Expected to receive first Phase 3 top-line data for RESPEG in Atopic Dermatitis (AD) in mid-2028. Expected to receive Phase 3 data for RESPEG in Alopecia Areata (AA) in 2029.
    • Data Presentation: Data regarding rhinosinusitis and allergy co-morbidity benefits to be presented at a medical meeting in early 2027.
    • Pipeline Timing: Phase 3 registration program for RESPEG in Atopic Dermatitis initiated in summer 2026; Phase 3 program for RESPEG in Alopecia Areata to commence in December 2026 (following months).
  • Business-Segment Outlook:

    • Product Differentiation (Durability): Anticipates RESPEG offers unique off-drug durability, with potential for patients to maintain response or deepen efficacy up to 12 months after stopping treatment (vs. Dupixent's 9-month maintenance with sham injections).
    • Dosing Regimen Optimization: Expects to move patients from an induction regimen (twice monthly for 6 months) to a maintenance regimen (monthly or quarterly) within the first year; projects potential for once-quarterly dosing starting Year 1 if off-drug durability is confirmed.
    • Phase 3 Design & Population:
      • Atopic Dermatitis: Three pivotal studies (total 510 patients each).
        • Zenith AD1: Monotherapy in biologic/JAK-experienced patients.
        • Zenith AD2: Add-on to topical corticosteroids (TCS) in mixed naive/experienced populations; expects high separation despite placebo noise from TCS.
        • Zenith AD3: Monotherapy testing in second-line+ setting.
      • Alopecia Areata: Single Phase 3 study of 850 patients (adolescents 12+) with mixed naive/JAK-experienced population to support registration.
    • Mechanism Validation: Preclinical data suggests RESPEG normalizes TH1, TH2, and TH17 pathways plus fibrotic signatures within 2 weeks of a single dose; expects systemic immunological normalization to drive long-term disease modification.
    • Comorbidity Targeting: Anticipates clinical labeling differentiation via dual efficacy in treating co-occurring asthma and allergic rhinosinusitis alongside atopic dermatitis.
  • Market and Competitive Outlook:

    • Competitive Positioning: Positions RESPEG as a novel Mechanism of Action (MOA) capable of disrupting the current market dominated by Dupixent (Dupilumab).
    • Market Gap: Aims to address the "perpetual dosing" requirement of current biologics (e.g., Dupixent twice monthly) by offering potential drug-free intervals after one year of treatment.
    • Label Differentiation:
      • Monotherapy: Prospectively testing efficacy in biologic/JAK-inhibitor refractory patients (second-line+).
      • Combination: Developing a label as a TCS add-on to cover global usage patterns where combination therapy is standard.
    • Adverse Event Profile: Expects low rescue medication usage and low discontinuation rates due to high-quality responses observed in Phase 2.
  • Macro / Industry Outlook:

    • Regulatory Strategy: FDA and EMA feedback drove the inclusion of TCS add-on arms (Zenith AD2) to capture global real-world usage; expects health authorities to accept a single Phase 3 study for Alopecia Areata approval.
    • Safety/Tolerability: Anticipates that patients discontinuing JAK inhibitors (often due to toxicity) will benefit from RESPEG's different safety profile.
  • Strategic Initiatives:

    • Phase 3 Activation: Launched three Phase 3 studies for Atopic Dermatitis in Summer 2026; initiating Alopecia Areata Phase 3 study in December 2026.
    • Label Expansion Strategy: Designing trials to capture broad labeling opportunities: monotherapy for biologic-naive and refractory patients, plus TCS-add-on for combination therapy markets.
    • Data Generation: Planning to submit Phase 2 maintenance data to medical journals (Lancet follow-up) and present rhinosinusitis data in early 2027.
  • Risks and Headwinds to Outlook:

    • Study Design Interpretation: Acknowledges potential challenges in comparing off-drug durability results to randomized withdrawal studies (like Dupixent's SOLO CONTINUE) due to the lack of sham injections in Nectar's design.
    • Patient Retention: Relies on "altruism" to maintain patient observation off-drug; dropouts could impact analysis of long-term durability, though "last observation carried forward" will be utilized.
    • Placebo Variance in Combination: Anticipates a slight increase in placebo response rates in TCS-add-on studies compared to monotherapy, though expects drug separation to remain high.
    • Uncertainty of Off-Drug Durability: While Phase 1 and 2 suggest durability, final proof in Phase 3 is contingent on confirming these effects in the larger, 12-month off-drug observation window.
  • Management Tone on the Future:

    • Confidence: Expressed high confidence in the Phase 3 designs and power calculations; described the Phase 3 initiation as a "very exciting time."
    • Differentiation Focus: Tone emphasizes that RESPEG's "off-drug durability" and "immune system normalization" are fundamentally distinct from current market leaders, positioning the company to capture significant market share if clinical endpoints are met.
    • Optimism: Management views the ability to potentially treat comorbidities (asthma, rhinosinusitis) and achieve long-term remission as "highly differentiating" and "disruptive" to the current therapeutic standard.
  • Miscellaneous:

    • Conferencing: Presentation took place at the 2026 Jeffries Global Healthcare Conference in London.
    • Scientific Context: References the 2025 Nobel Prize (implied by "last year's Nobel Prize" relative to the 2026 conference date) on immune tolerance/Tregs as the foundational science for the pipeline.
    • Historical Data: Phase 2 data published in the Lancet; Phase 1 showed 9 months of durability in a 40-patient cohort.
Company
NEKTAR THERAPEUTICS
Keywords
NEKTAR THERAPEUTICS